KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel ima edilen olasılık
Above 8% 92%9 seçenek arasında lider
Piyasa kalitesi
62 / 100
Orta kalite24s Hacim
₺147,1 B
Likidite
₺127,7 B
Orta likiditeSpread
1.0 pt
Dar spreadPiyasa verileri
6 dakika önce güncellendi
9 Eyl 26 02:00 UTC31 Mar 27 05:00 UTC
Trendler
0%
0%
0%
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
Medtronic cardiovascular organic growth in fiscal 2027
KalshiWill I believe the post "Cardiovascular disease is a solved problem" is broadly correct in August 2028?
Manifold MarketsWhen will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWill 3 mg THC beverages be federally legal to sell?
KalshiWill there be >250k tech layoffs in 2027 according to Layoffs.fyi?
Manifold MarketsWill Aurelia Song abandon Nectome before 2041?
Manifold MarketsKurallar
If Medtronic plc reports Above 8% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
Uzlaşma kaynağı:Fiscal.ai
- Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company.
- All trademarks, logos, and brand names are the property of their respective owners.
- If Medtronic plc reports Above 9% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- If Medtronic plc reports Above 10% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- If Medtronic plc reports Above 10.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
Açık piyasalar
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Toplam Hacim
- ₺879,6 Mn
- 24s Hacim
- ₺1,2 Mn
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Toplam Hacim
- ₺51,9 Mn
- 24s Hacim
- ₺235,5 B
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 daha fazla sonuç
- Toplam Hacim
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+2.0pt61%
+2 daha fazla sonuç
- Toplam Hacim
- ₺48,9 Mn
- 24s Hacim
- ₺95,6 B
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Toplam Hacim
- ₺34,6 Mn
- 24s Hacim
- ₺62,2 B
KALSHIWhen will Beam Therapeutics submit a BLA for Risto-cel?
- before April 202793%
- before 202756%
- before December49%
+3 daha fazla sonuç
- Toplam Hacim
- ₺1,1 Mn
- 24s Hacim
- ₺57,5 B
- Which countries will report an Ebola disease case before October?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Heidi Overton confirmed as FDA Commissioner by which date?
- Will the FDA approve retatrutide?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Ebola pandemic in 2026?
- Measles cases in U.S. by September 30?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- FDA approves Retatrutide this year?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
Sık sorulan sorular
- Medtronic cardiovascular growth in Q2 için güncel oranlar nedir?
- Kalshi, 10 Eylül 2026 itibarıyla Above 8% için 92% fiyatlıyor.
- Medtronic cardiovascular growth in Q2 ne zaman sonuçlanacak?
- Medtronic cardiovascular growth in Q2 için öngörülen sonuçlanma tarihi 31 Mart 2027.
- Medtronic cardiovascular growth in Q2 nasıl sonuçlandırılıyor?
- Kalshi bu piyasayı şu şekilde sonuçlandırır: If Medtronic plc reports Above 8% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.